including a recent approval in neoadjuvant/adjuvant treatment of early-stage non-small cell lung cancer (NSCLC). It is the second drug in the PD-1/PD-L1 inhibitor class to be cleared in a ...

Incyte's first attempt to get FDA approval for its PD-1 inhibitor Zynyz for squamous ... but picked up its first approval in the rare tumour Merkel cell carcinoma last year. Incyte had previously ...

Crown BioScience experts explore organoid models and high-content imaging to evaluate T-cell-targeted therapies and ...

Thanks to the tireless efforts of people like San Luis Obispo resident Frank Kalman and his nonprofit, End Kids Cancer, there have been major advances in pediatric oncology in recent years. Here's Kal ...

Recent studies highlight the potential pathophysiology and presentation of immune checkpoint inhibitor–associated cutaneous ...

There is currently no strong evidence that additional immune therapy benefits patients with renal cell carcinoma who were ...

LARKSPUR, CA, USA I April 14, 2025 I Aulos™ Bioscience, an immuno-oncology company working to revolutionize cancer care through development of ...

A multinational research team of clinicians and scientists from South Korea and Singapore has published positive findings ...

AU-007, combined with Opdivo and low-dose aldesleukin, has entered a phase 2 melanoma trial, with early data showing activity ...

Oncology Clinical Trials Market has been steadily growing over the years due to increasing incidence of cancer, advancements ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, ...

SparX Biopharmaceutical Corp. announced today that it will present clinical updates on its lead asset, SPX-303, a first-in-class anti-LILRB2/PD-L1 bispecific antibody, during the Trial-in-Progress ...